Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting.
Melissa Brammer
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Deepa Lalla
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Geneviève Gauthier
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Annie Guérin
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Philippe Giguere-Duval
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Eric Q. Wu
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Eduardo Santos
Employment or Leadership Position - Genentech